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Prognostic Value of Fluorodeoxyglucose Uptake in
Non-small Cell Lung Cancer
Time for Standardization and Validation
Christophe Dooms, MD, PhD, and Johan Vansteenkiste, MD, PhD
Most clinical studies on the use of positron emission tomography with fluorodeoxy-glucose (FDG-PET) in non-small cell lung cancer (NSCLC) have focused on its role
in noninvasive diagnosis and staging.1 Another striking feature of the PET lung cancer
literature is that (semi) quantitative measures of FDG uptake may also serve as a surrogate
marker of the biologic aggressiveness of the tumor. Initial in vitro studies demonstrated
that FDG uptake is related to the number of viable tumor cells and their doubling time.2
This led to the hypothesis that FDG uptake might be related to outcome, and numerous
studies reported on the potential use of FDG-PET in the prediction of recurrence and
survival rates of NSCLC, either newly diagnosed or after induction therapy in multimo-
dality approaches.3 More recent studies unraveled how FDG uptake might be related to the
different biologic pathways involved in lung cancer progression.4,5 A high-baseline FDG
uptake was also reported to be a predictor of poor outcome for breast, thyroid, esophageal,
and colorectal cancer, as well as sarcomas and gliomas.
In this issue of Journal of Thoracic Oncology, Paesmans et al.6 report on an updated
systematic review of 21 evaluable studies relating the degree of FDG uptake of the
primary tumor at diagnosis to the prognosis of 2637 patients. Most of these studies were
retrospective single-institution studies in predominantly surgical cohorts of patients. They
examined the correlation of FDG uptake of the primary tumor, measured as standardized
uptake value (SUV), and survival. Patients were dichotomized in low and high SUV
categories by using the median SUV or the “best cutoff ” SUV. Overall, patients with high
SUV had a significantly worse prognosis: hazard ratio 2.1 (95% confidence interval:
1.72–2.59), a result in line with their previous report,7 but with sharper confidence
intervals. Sensitivity analyses for period of publication or method of dichotomization gave
small variations in the results.
Several clinical and methodological elements need to be considered when trying to
interpret this observation. First, the tumor, node, metastasis stage at diagnosis remains the
most important prognostic factor, even if it does not give an explanation for the
differences in survival within a similar stage, probably due to biologic factors of tumor
aggressiveness, which could be estimated by metabolic imaging of FDG uptake. However,
as the authors acknowledge, this systematic review does not allow to assess the indepen-
dent prognostic value of SUV compared with tumor, node, metastasis stage, because many
studies in it did not report multivariate analysis of the different prognostic factors. Their
results also suggest that the prognostic value of FDG uptake may be more important in
early-stage NSCLC, possibly because the prognostic impact of FDG uptake is too much
diluted in patients with advanced stage and major anatomic extent of the tumor.
Second, the measuring tool SUV is not “standardized” at all.8 Indeed, a variety of
factors can affect the (semi)quantitative determination of FDG uptake. Patient factors are
body weight and plasma glucose level. Imaging acquisition factors are the dose of FDG
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injected and the interval between FDG injection and emission
scanning (i.e., uptake period). Image processing factors are
partial volume effects, reconstruction algorithms, and whether
SUVmax (i.e., obtained for a one-pixel region of interest corre-
sponding to the maximum pixel value in the tumor) or another
SUV measure is used. Therefore, the SUV measurement is at
best constant on one scanner in one center. This also explains
why the use of FDG-PET for diagnosis and staging (where
visual analysis of the images is at least as good as SUV9) has
gained widespread clinical use and acceptance, whereas other
applications remain limited to dedicated or research centers.
So where could we move from here? For sure, the
ongoing effort to perform an individual patient-based meta-
analysis—endorsed by the International Association for the
Study of Lung Cancer Staging Committee10—would be able
to solve some of our current questions. The independent
value of SUV in relation to factors such as stage or histology
could be assessed. Whether these data will shed light on the
different problems related to standardization of PET, and
especially the choice of an optimal “prognostic SUV cutoff,”
is uncertain. Nonetheless, the results of such a meta-analysis
will be of help in the proper design of prospective multicenter
studies to address these issues in a more definitive way.
Although using “high” uptake of FDG to individualize
adjuvant chemotherapy in subgroups of surgically resected
stage I NSCLC—as suggested in some ongoing clinical
trials—may be an appealing idea, this is surely not ready for
clinical practice until we have more data. But even then, it is
questionable whether FDG-PET will be able to win the race
against the rapidly increasing genomic and proteomic infor-
mation, providing us with a detailed prognostic signature of
lung cancer, which most likely will allow us to tailor adjuvant
therapies in clinical practice in the near future.11,12 However,
for both methods, standardization and validation will be the
critical issue in years to come.
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